Bridging communities in the field of nanomedicine

Blanka Halamoda-Kenzaoui, Simon Baconnier, Thierry Bastogne, Didier Bazile, Patrick Boisseau, Gerrit Borchard, Sven Even Borgos, Luigi Calzolai, Karin Cederbrant, Gabriella Di Felice, Tiziana Di Francesco, Marina A Dobrovolskaia, Rogério Gaspar, Belén Gracia, Vincent A Hackley, Lada Leyens, Neill Liptrott, Margriet Park, Anil Patri, Gert RoebbenMatthias Roesslein, René Thürmer, Patricia Urbán, Valérie Zuang, Susanne Bremer-Hoffmann

Research output: Contribution to journalArticlepeer-review

Abstract

An early dialogue between nanomedicine developers and regulatory authorities are of utmost importance to anticipate quality and safety requirements for these innovative health products. In order to stimulate interactions between the various communities involved in a translation of nanomedicines to clinical applications, the European Commission's Joint Research Centre hosted a workshop titled "Bridging communities in the field of Nanomedicine" in Ispra/Italy on the 27th -28th September 2017. Experts from regulatory bodies, research institutions and industry came together to discuss the next generation of nanomedicines and their needs to obtain regulatory approval. The workshop participants came up with recommendations highlighting methodological gaps that should be addressed in ongoing projects addressing the regulatory science of nanomedicines. In addition, individual opinions of experts relevant to progress of the regulatory science in the field of nanomedicine were summarised in the format of a survey.

Original languageEnglish
Pages (from-to)187-196
Number of pages10
JournalRegulatory Toxicology and Pharmacology
Volume106
DOIs
Publication statusPublished - Aug 2019

Keywords

  • Decision Making
  • Decision Support Systems, Clinical
  • Humans
  • Nanomedicine
  • Surveys and Questionnaires

Fingerprint Dive into the research topics of 'Bridging communities in the field of nanomedicine'. Together they form a unique fingerprint.

Cite this